Rx drug information, pharmaceutical research, clinical trials, news, and more
A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. [2013]
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. [2012]
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. [2013]
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. [2014]
Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. [2013]
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. [2013]
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. [2013]
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. [2012]
All Rights reserved - Copyright DrugLib.com, 2006-2017